Amaran Biotech Wins Asia-Pacific Biopharma Excellence Award 2025
TAIPEI, Taiwan, March 13, 2025 (GLOBE NEWSWIRE) -- New-generation Contract Development and Manufacturing Organization (CDMO) Amaran Biotech has been awarded the prestigious 'Bioprocessing Excellence in Taiwan' honor at the Asia-Pacific Biopharma Excellence Awards 2025 ceremony, hosted by renowned consulting firm IMAPAC in Singapore on March 12.
Established in 2017, the Asia-Pacific Biopharma Excellence Awards recognize outstanding achievements in bioprocessing, logistics, supply chain management, antibody-drug conjugates (ADC), and clinical trials experts, organizations and technologies across Asia. The awards aim to foster the advancement of the biopharmaceutical industry. Amaran Biotech's high-purity AB-801 adjuvant, produced through its innovative bioprocessing technology, triumphed after a process including nomination, shortlisting, and public voting.
An adjuvant is key component added to vaccines to enhance the body's immune response, boosting vaccine efficacy while reducing the required dosage per shot. Amaran Biotech's AB-801 offers application capabilities comparable to the globally recognized adjuvant QS-21, which is derived from the soap bark tree (Quillaja saponaria) native to Chile, Bolivia, and Peru. Saponin-based adjuvants have been utilized in several vaccines, including Shingrix® by GSK for shingles and the Novavax COVID-19 vaccine.
Dr. Tessie Che, Chairperson and General Manager of Amaran Biotech, stated: 'AB-801 is a GMP-grade QS-21 adjuvant, and we are one of the few CDMOs worldwide capable of manufacturing this product. This honor recognizes our team's dedication and hard work. We will continue to enhance our technologies to deliver high-quality bioprocessing solutions to global clients.' Currently, AB-801 is supplied to a leading pharmaceutical company worldwide, and has been adopted by research institutions and universities across Europe, North America, China, and Japan, as well as vaccine research organizations and manufacturers in China and India. Moving forward, Amaran Biotech will further expand its production capacity and ensure sustainable supply to serve more international clients and drive the global biotech industry forward.About Amaran BiotechAmaran Biotech is a CDMO specializing in drug process development, analytical services and cGMP manufacturing of high-value biopharmaceuticals. Amaran Biotech's state-of-the-art manufacturing facility is in the Hsinchu Biomedical Science Park and has been granted the PIC/S GMP certification from the TFDA since 2017. The company has also been audited and fully qualified by the regulatory agencies and third-party auditors from the USA and the EU. For more information, visit www.amaranbiotech.com
Media Contact: Doreen Lin doreen.lin@amaranbiotech.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5d0faf8b-ec8a-4f17-903d-30888555035fSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
4 minutes ago
- Bloomberg
India's Insurance Giant Turns to Wall Street Banks to Hedge Risk
Life Insurance Corp. of India is working with some of Wall Street's largest banks to hedge its liabilities, according to people familiar with the matter. The nation's largest insurer has entered into $1 billion worth of bond forward rate agreements with banks including JPMorgan Chase & Co. and Bank of America Corp. over the past two months, the people said, asking not to be identified as they are not authorized to speak publicly.
News24
5 minutes ago
- News24
Markets boosted after EU, US strike trade deal
Stock markets rose in Europe and Asia on Monday after the European Union and United States hammered out a deal to avert a potentially damaging trade war. News of the deal, announced by US president Donald Trump and European Commission head Ursula von der Leyen on Sunday, followed a series of US trade agreements last week, including with Japan, and comes ahead of a new round of China-US talks. Investors were also gearing up for a busy week of data, central bank decisions and earnings from some of the world's biggest companies. Trump and von der Leyen announced at his golf resort in Scotland that a baseline tariff of 15 percent would be levied on EU exports to the United States. "We've reached a deal. It's a good deal for everybody. This is probably the biggest deal ever reached in any capacity," Trump said, adding that the levies would apply across the board, including for Europe's crucial automobile sector, pharmaceuticals and semiconductors. Brussels also agreed to purchase "$750 billion worth of energy" from the United States, as well as make $600 billion in additional investments. "It's a good deal," von der Leyen said. "It will bring stability. It will bring predictability. That's very important for our businesses on both sides of the Atlantic." Equities built on their recent rally, fanned by relief that countries were reaching deals with Washington. Paris rose one percent, with Frankfurt and London also tracking gains in Hong Kong, Shanghai, Sydney, Seoul, Wellington, Taipei and Jakarta. Tokyo fell for a second day, having soared about five percent on Wednesday and Thursday in reaction to Japan's US deal. Singapore, Manila and Mumbai were also lower. The broad gains came after another record day for the S&P 500 and Nasdaq on Wall Street. "The news flow from both the extension with China and the agreement with the EU is clearly market-friendly, and should put further upside potential into the euro... and should also put renewed upside into EU equities," said Chris Weston at Pepperstone. Traders are gearing up for a packed week, with a delegation including US Treasury Secretary Scott Bessent holding fresh trade talks with a Chinese team headed by Vice Premier He Lifeng in Stockholm. While in April both countries imposed tariffs that reached triple-digits, US duties this year have temporarily been lowered to 30 percent and China's countermeasures slashed to 10 percent. The 90-day truce, instituted after talks in Geneva in May, is set to expire on August 12. China said it was seeking "mutual respect and reciprocity" in the talks. Also on the agenda are earnings from tech titans Amazon, Apple, Meta and Microsoft, as well as data on US economic growth and jobs. The Federal Reserve's latest policy meeting is expected to conclude with officials standing pat on interest rates, though investors are keen to see what their views are on the outlook for the rest of the year in light of Trump's tariffs and recent trade deals. "We think the data supports a Fed on hold in July, but absent a significant upside surprise in the upcoming inflation data, September could be a 'live' meeting for a resumption of rate cuts, especially if economic activity data and possibly overwhelming political pressure force the Fed's hand," said Michael Krautzberger at Allianz. The Bank of Japan is also forecast to hold off on any big moves on borrowing costs. By mid-morning, the JSE's All-Share index was flat, with Valterra down more than 2% after releasing its results.
Bloomberg
34 minutes ago
- Bloomberg
Goldman Picks New Leaders for Japan Capital Markets Business
Goldman Sachs Group Inc. is shuffling part of its Tokyo leadership to boost its capital markets business, as Japan's corporate governance overhaul generates more dealmaking opportunities for investment banks. The Wall Street firm's local securities arm has appointed Yojiro Kunitomo and Yusuke Minowa as capital solutions group co-heads, according to an internal memo seen by Bloomberg News and confirmed by a spokeswoman.
